surfactants in waste waters, the major source of river pol- lution. Chemosphere. 72(1):115–121. Biegel LB, Hurtt ME, Frame SR, O’Connor JC, Cook JC. 2001. Mechanisms of extrahepatic tumor induction by peroxi- some proliferators in male CD rats. Toxicol Sci 60(1):44–55. Bloom MS, Kannan K, Spliethoff HM, Tao L, Aldous KM, Vena JE. 2010. Exploratory assessment of perfluorinated compounds and human thyroid function. Physiol Behav 99(2):240–245. Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, et al. 2002. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci 69:244–257. C8 Health Project. 2009. C8 Health Project Results. Available: http://www.hsc.wvu.edu/som/cmed/c8/results/ [accessed 7 July 2010]. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. 2007a. Serum concentrations of 11 poly- fluoroalkyl compounds in the US population: data from the National Health and Nutrition Examination Survey (NHANES). Environ Sci Technol 41:2237–2242. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 2007b. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and comparisons with NHANES 1999–2000. Environ Health Perspect 115:1596–1602. Chang SC, Thibodeaux JR, Eastvold ML, Ehresman DJ, Bjork JA, Froehlich JW, et al. 2007. Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS). Toxicology 234(1,2):21–33. Costa G, Sartori S, Consonni D. 2009. Thirty years of medical surveillance in perfluooctanoic acid production workers. J Occup Environ Med 51:364–372 DeWitt JC, Copeland CB, Strynar MJ, Luebke RE. 2008. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ Health Perspect 116:644–650. Dewitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, et al. 2009. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of per- oxisome proliferator-activated receptor alpha. Crit Rev Toxicol 39:76–94. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. 2006a. Community exposure to perfluorooctanoate: rela- tionships between serum concentrations and exposure sources. J Occup Environ Med48:759–770. Emmett EA, Zhang H, Shofer FS, Zhang H, Freeman D, Desai C, et al. 2006b. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J Occup Environ Med 48:771–779. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, et al. 2008. Multiple organic anion transporters contrib- ute to net renal excretion of uric acid. Physiol Genomics 33(2):180–192. Eriksen KT, Sørensen M, McLaughlin JK, Lipworth L, Tjønneland A, Overvad K, et al. 2009. Perfluorooctanoate and perfluo- rooctanesulfonate plasma levels and risk of cancer in the general Danish population. J Natl Cancer Inst 101:605–609. Fei C, McLaughlin JK, Lipworth L, Olsen J. 2008a. Prenatal exposure to PFOA and PFOS and maternally reported developmental milestones in infancy. Environ Health Perspect 116:1391–1395. Fei C, McLaughlin JK, Lipworth L, Olsen J. 2009. Maternal levels of perfluorinated chemicals and subfecundity. Hum Reprod 1(1):1–6. Fei C, McLaughlin JK, Tarone R, Olsen J. 2007. Perfluorinated chemicals and fetal growth: a study in the Danish National Birth Cohort. Environ Health Perspect 115:1677–1682. Fei C, McLaughlin JK, Tarone R, Olsen J. 2008b. Fetal growth indicators and perfluorinated chemicals. A study in the Danish National Birth Cohort. Am J Epidemiol 168:66–72. Feig DI, Soletsky B, Johnson RJ. 2008. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essen- tial hypertension: a randomized trial. JAMA 300:924–932. Frisbee SJ, Brooks AP, Maher A, Flensborg P, Arnold S, Fletcher T, et al. 2009. The C8 Health Project: design, methods, and participants. Environ Health Perspect 117:1873–1882. Frisbee SJ, Shankar A, Knox SS, Steenland K, Fletcher T, Savitz DA, et al. In press. The C8 Health Project: associations between perfluorooctanoic acid and perfluorooctane- sulfonic acid and serum lipids in children. Arch Pediatr Adolesc Med. Fromme H, Tittlemier SA, Völkel W, Wilhelm M, Twardella D. 2009. Perfluorinated compounds—exposure assessment for the general population in Western countries. Int J Hyg Environ Health 212:239–270. Gilliland FD, Mandel JS. 1996. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am J Ind Med 29(5):560–568. Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, et al. 2009. A reexamination of the PPAR-α activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ Health Perspect 117:1664–1672. Hamm MP, Cherry NM, Chan E, Martin JW, Burstyn I. 2009. Maternal exposure to perfluorinated acids and fetal growth. J Expo Sci Environ Epidemiol; doi:10.1038/jes.2009.57 [28 October 2009]. Hölzer J, Midasch O, Rauchfuss K, Kraft M, Reupert R, Angerer J, et al. 2008. Biomonitoring of perfluorinated compounds in children and adults exposed to perfluoro- octanoate-contaminated drinking water. Environ Health Perspect 116:651–657. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. 2004. Perfluorooctane sulfonate (PFOS) and related per- fluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204–1207. Joensen UN, Bossi R, Leffers H, Jensen AA, Skakkebaek NE, Jørgensen N. 2009. Do perfluoroalkyl compounds impair human semen quality? Environ Health Perspect 117:923–927. Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, et al. 2004. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 38:4489–4495. Kennedy GL Jr, Butenhoff JL, Olsen GW, O’Connor JC, Seacat AM, Perkins RG, et al. 2004. The toxicology of perfluorooctanoate. Crit Rev Toxicol 34:351–384. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, et al. 2003. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33(6):655–780. Kreckmann KH, Sakr CJ, Leonard RC, Dawson BJ. 2009. Estimation and validation of biomarker-based exposures for historical ammonium perfluorooctanoate. J Occup Environ Hyg 6:511–516. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366–394. Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. 2008. Retrospective cohort mortality study of workers in a poly- mer production plant including a reference population of regional workers. Ann Epidemiol 18:15–22. Lin CY, Lin LY, Chiang CK, Wang WJ, Su YN, Hung KY, et al. 2010. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol 105(6):1354–1363. Loveless SE, Finlay C, Everds NE, Frame SR, Gillies PJ, O’Connor JC, et al. 2006. Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). Toxicology 220:203–217. Loveless SE, Hoban D, Sykes G, Frame SR, Everds NE. 2008. Evaluation of the immune system in rats administered lin- ear ammonium perfluorooctanoate. Toxicol Sci 105:86–96. Lundin JI, Alexander BH, Olsen GW, Church TR. 2009. Ammonium perfluorooctanoate production and occupa- tional mortality. Epidemiology 20(6):921–928. MacNeil J, Steenland K, Shankar A, Ducatman A. 2009. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res 109(8):997–1003. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. 2010. Association between serum perfluoroctanoic acid (PFOA) and thyroid disease in the NHANES study. Environ Health Perspect 118:686–692. Minnesota Department of Health. 2009. East Metro Perfluoro- chemical Biomonitoring Pilot Project: Report to the Community. Available: http://www.health.state.mn.us/divs/ eh/tracking/pilotpfcbrief709.pdf [accessed 24 April 2010]. Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, et al. 2008. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 108:56–62. Nakagawa H, Hirata T, Terada T, Jotubha P, Miura D, Harada KH, et al. 2008. Roles of organic anion transporters Environmental Health Perspectives • volume 118 | number 8 | August 2010 Epidemiology of PFOA in the renal excretion of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 103(1):1–8. Nelson J, Hatch E, Webster T. 2010. Exposure to polyfluoro- alkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 118:197–202. Nolan LA, Nolan JM, Shofer FS, Rodway NV, Emmett EA. 2009a. Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluoro- octanoic acid (PFOA)-contaminated public drinking water. Reprod Toxicol 29(2):147–155. Nolan LA, Nolan JM, Shofer FS, Rodway NV, Emmett EA. 2009b. The relationship between birth weight, gestational age and perfluorooctanoic acid (PFOA)-contaminated drinking water. Reprod Toxicol 27:231–238. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2000. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol 23:603–620. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2003. Epidemiologic assessment of worker serum perfluorooc- tanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 45:260–270. Olsen GW, Burris J, Ehresman D, Forehlich J, Seaca A, Butenhoff J, et al. 2007a. Half-life of serum elimination of perfluorooctanesulfonate, perluorohexanesulfonate, and perefluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298–1365. Olsen GW, Burris JM, Mandel JH, Zobel LR. 1999. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med 41(9):799–806. Olsen GW, Butenhoff JL, Zobel LR. 2009. Perfluoroalkyl chem- icals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 27:212–230. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. 1998. An epidemiologic investigation of repro- ductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med 40:614–622. Olsen GW, Mair DC, Reagen WK. 2007b. Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and per- fluorooctanoate (PFOA) concentrations in American Red Cross blood donors. Chemosphere 68:105–111. Olsen GW, Zobel LR. 2007. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health 81:231–246. Pistocchio A, Loos R. 2009. A map of European emissions and concentrations of PFOS and PFOA. Environ Sci Technol 43(24):9237–9244. Ren H, Vallanat B, Nelson DM, Yeung LW, Guruge KS, Lam PK, et al. 2009. Evidence for the involvement of xenobiotic- responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod Toxicol 27(3–4):266–267. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. 2007a. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a gen- eral health survey in a cohort of occupationally exposed workers. J Occup Environ Med 49:1086–1096. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. 2007b. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium per- fluorooctanoate. J Occup Environ Med 49:872–879. Sakr CJ, Symons JM, Kreckmann KH, Leonard RC. 2009. Ischaemic heart disease mortality study among work- ers with occupational exposure to ammonium perfluoro- octanoate. Occup Environ Med 66:699–703. Savitz DA. 2007. Biomarkers of perfluorinated chemicals and birthweight [Editorial]. Environ Health Perspect 115:A528–A529. Shankar A, Klein R, Klein BE, Nieto FJ. 2006. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 20:937–945. Sibinski L. 1987. Final report of a 2 year oral (diet) toxic- ity and carcinogenicity study of fluorochemical Fc-143 (perfluorooctanane ammonium carbodylate) in rats. Vol. 1–4. Exp. No. 0281CR0012; 8EHQ-1087-0394. Minneapolis:3M Company/RIKER. So MK, Yamashita S, Taniyasu S, Jiang Q, Giesy JP, Chen K, 1107